Fig 8. Prognostic significance of PD-L1, DARC and DNA mismatch repair proteins MSH2 and PMS2 in human CRC treated with and without neoadjuvant FOLOFOX (scale bar = 50 μm for H&E and scale bar = 100 μm for IHC).

Colorectal adenocarcinoma sections showing negative expression of the PD-L1, DARC and PMS2 and positive expression of MSH2 in mucinous CRC pre and post-FOLFOX treatment (A and B), and pre and post-FOLFOX treated CRC NOS (C—E).